Ligand Pharmaceuticals Inc.
LGND
$293.99
-3.10%
Ligand Pharmaceuticals Inc. is a biopharmaceutical company that develops and acquires technologies to aid in creating medicine, generating revenue through royalties, license and milestone payments, and sales of its Captisol material. It operates as a royalty aggregator and drug discovery partner, distinct from traditional biotech firms due to its asset-light model focused on partnerships and licensing. The current investor narrative centers on Ligand's transformation into a leading biopharma royalty aggregator, highlighted by its April 2026 acquisition of XOMA Royalty, which is expected to accelerate profit growth and strengthen its competitive position. Attention is also driven by strong recent stock performance, with the stock up over 120% in the past year, reflecting optimism around its royalty-driven revenue model and expanding pipeline.…
LGND
Ligand Pharmaceuticals Inc.
$293.99
Related headlines
Investment Opinion: Should I buy LGND Today?
Rating: Buy. Ligand's asset-light royalty model, high gross margins, and strong balance sheet position it for long-term value creation, supported by unanimous analyst buy ratings and an average target of $311.30.
Supporting evidence: Revenue grew 14.1% YoY in Q1 2026, gross margin is 97.5%, free cash flow TTM is $123M, and the trailing PE of 29.4x is reasonable given the growth trajectory. The forward PE of 26.3x implies expected earnings growth, and the high analyst target of $388 offers 27.9% upside.
Risks & Conditions: The biggest risks are inconsistent profitability and high valuation multiples. This Buy rating would be downgraded to Hold if revenue growth falls below 10% or if the stock exceeds the high target without fundamental improvement. The stock appears fairly valued relative to its growth prospects, but not overvalued given the strong momentum and analyst support.
Sign up to view all
LGND 12-Month Price Forecast
Ligand's unique royalty aggregator model, high margins, and strong balance sheet provide a solid foundation for growth. The XOMA acquisition is a key catalyst that could accelerate profit growth and strengthen its market position. While valuation is elevated, the unanimous analyst support and strong technical momentum suggest continued upside. The base case of moderate growth is most likely, but the bull case has a meaningful probability given the company's track record. We would upgrade our stance if revenue growth consistently exceeds 15%, and downgrade if profitability fails to materialize or if the stock loses its technical support levels.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Ligand Pharmaceuticals Inc.'s 12-month outlook, with a consensus price target around $311.30 and implied upside of +5.9% versus the current price.
Average Target
$311.30
0 analysts
Implied Upside
+5.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$247 - $388
Analyst target range
Ligand is covered by 10 analysts, with a consensus recommendation of 'strong buy' (mean rating 1.22 on a 1-5 scale). The average target price is $311.30, implying a modest 2.6% upside from the current price of $303.39. The distribution is bullish, with no hold or sell ratings, indicating strong conviction. The target range spans from a low of $247.00 to a high of $388.00. The high target of $388.00 implies 27.9% upside and likely assumes successful integration of the XOMA acquisition, continued royalty growth, and potential multiple expansion. The low target of $247.00 implies 18.6% downside, potentially pricing in execution risks or slower-than-expected growth. Recent institutional ratings show consistent bullishness: RBC Capital, B of A Securities, Stifel, and Citigroup have all reiterated 'Buy' or 'Outperform' ratings in the past three months. The wide spread between low and high targets ($141) indicates moderate uncertainty, but the unanimous buy recommendations suggest analysts are confident in the company's direction. The strong consensus supports the positive technical and fundamental outlook.
Bulls vs Bears: LGND Investment Factors
Ligand presents a compelling bull case as a royalty aggregator with high margins, strong balance sheet, and unanimous analyst support. The stock's 120% annual gain reflects optimism around the XOMA acquisition and expanding pipeline. However, bears point to inconsistent profitability, elevated valuation multiples, and limited near-term upside to the average target. The single most important tension is whether the company can sustain its revenue growth trajectory and achieve consistent profitability, which would justify its premium valuation. Currently, the bull case has stronger evidence given the improving fundamentals and strong momentum, but the stock's price already reflects much of the good news.
Bullish
- Strong Revenue Growth Trajectory: Revenue grew 14.1% YoY in Q1 2026 to $51.7M, driven by royalty and contract revenue. The XOMA acquisition is expected to further accelerate profit growth, positioning Ligand as a leading biopharma royalty aggregator.
- High Gross Margins Reflect Asset-Light Model: Gross margin is 97.5% (Q1 2026) and 97.6% trailing, typical for a royalty-based business. This high margin provides operating leverage and cash flow generation.
- Strong Balance Sheet with Low Debt: Current ratio of 22.2 and debt-to-equity of 0.44 indicate minimal financial risk. Free cash flow TTM of $123M provides ample liquidity for reinvestment or acquisitions.
- Unanimous Analyst Buy Consensus: All 10 analysts rate the stock a 'strong buy' with a mean rating of 1.22. The average target of $311.30 implies 2.6% upside, while the high target of $388 suggests 27.9% potential.
Bearish
- Inconsistent Profitability and Net Losses: Q1 2026 net loss of -$13.3M and negative EPS of -$0.67, though improved from -$42.5M loss a year ago. Net margin was -25.8% in Q1, highlighting earnings volatility.
- High Valuation Multiples: Trailing PE of 29.4x and PS of 13.6x are elevated relative to historical averages. The PCF ratio of 74.1x suggests the market is pricing in aggressive future cash flow growth.
- Modest Upside to Average Analyst Target: The average analyst target of $311.30 offers only 2.6% upside from the current price of $303.39. This limited near-term upside may cap further gains.
- Revenue Lumpiness from Milestone Payments: Quarterly revenue is volatile, ranging from $45.3M (Q1 2025) to $115.5M (Q3 2025). This unpredictability makes earnings difficult to forecast and may lead to misses.
LGND Technical Analysis
Ligand's stock is in a sustained uptrend, with a 1-year price change of +120.5%, significantly outperforming the S&P 500's +18.4%. The current price of $303.39 sits at 92.9% of its 52-week range ($129.55–$326.63), indicating the stock is near its highs, suggesting strong momentum but also potential overextension. The price is just 7.1% below the 52-week high, reflecting bullish sentiment and a market that is pricing in continued positive developments. Short-term momentum is accelerating, with a 1-month change of +15.3% and a 3-month change of +30.9%, both outpacing the S&P 500's respective gains of 0.3% and 4.7%. This acceleration aligns with the longer-term uptrend, confirming strong buying pressure. The relative strength index (RSI) is not directly provided, but the consistent upward price action and volume of 278,327 shares suggest active participation. The 52-week low of $129.55 provides a key support level, while the 52-week high of $326.63 acts as resistance. A breakout above $326.63 would signal a continuation of the uptrend, potentially targeting new highs, while a breakdown below $129.55 would indicate a major reversal. The stock's beta of 0.98 indicates volatility roughly in line with the market, meaning it carries similar systematic risk to the S&P 500.
Beta
0.98
0.98x market volatility
Max Drawdown
-14.1%
Largest decline past year
52-Week Range
$130-$327
Price range past year
Annual Return
+111.4%
Cumulative gain past year
| Period | LGND Return | S&P 500 |
|---|---|---|
| 1m | +7.0% | -0.6% |
| 3m | +29.7% | +5.4% |
| 6m | +47.4% | +8.3% |
| 1y | +111.4% | +18.3% |
| ytd | +54.6% | +8.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
LGND Fundamental Analysis
Ligand's revenue trajectory shows a mixed but generally improving trend. In Q1 2026, revenue was $51.7 million, up 14.1% year-over-year from $45.3 million in Q1 2025. However, revenue has been volatile: Q3 2025 saw a spike to $115.5 million, while Q4 2025 was $59.7 million. The revenue segments are dominated by royalties ($50.5 million) and contract revenue ($66.7 million), with intangible royalty assets contributing $40.7 million. The growth in royalties and the XOMA acquisition are key drivers, but the lumpy nature of milestone payments creates quarterly variability. Profitability is inconsistent. In Q1 2026, Ligand reported a net loss of -$13.3 million and negative EPS of -$0.67, compared to a net loss of -$42.5 million in Q1 2025. However, gross margin remains extremely high at 97.5% (Q1 2026) and 97.6% (trailing), typical for a royalty-based model. Operating margin was 33.6% in Q1 2026, but net margin was -25.8% due to other expenses. The company has shown it can be profitable, as in Q3 2025 with net income of $117.3 million and a net margin of 101.6%. The trajectory toward profitability is uneven, but the narrowing loss year-over-year is a positive sign. Ligand's balance sheet is strong with a current ratio of 22.2 and a debt-to-equity ratio of 0.44, indicating low financial risk. Free cash flow (TTM) is $123.0 million, and the company generated $48.7 million in operating cash flow in Q1 2026. ROE is 12.2%, reflecting decent returns on equity. The company has ample liquidity, with cash at end of Q1 2026 of $115.1 million, and it does not pay dividends, allowing reinvestment. The FCF yield is not directly provided but implied by the PCF ratio of 74.1, suggesting the stock is priced for high future cash flow growth.
Quarterly Revenue
$51722000.0B
2026-03
Revenue YoY Growth
+14.1%
YoY Comparison
Gross Margin
96.0%
Latest Quarter
Free Cash Flow
$122956000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is LGND Overvalued?
Since net income is positive on a trailing twelve-month basis (EPS of $0.034), the trailing PE ratio is the primary valuation metric. The trailing PE is 29.4x, while the forward PE is 26.3x, implying the market expects earnings growth. The gap between trailing and forward PE suggests modest earnings expansion is anticipated. Compared to the biotechnology industry, Ligand's PE of 29.4x is at a premium to the sector average (industry average PE not provided, but biotech typically trades at higher multiples due to growth potential). The PS ratio of 13.6x is also elevated, reflecting the market's willingness to pay a premium for its royalty-based revenue model. Historically, Ligand's trailing PE has ranged from negative (during loss quarters) to over 100x. The current PE of 29.4x is near the lower end of its historical range over the past few years, where it has been as high as 113.7x (Q2 2025) and as low as negative. This suggests the stock is not excessively overvalued relative to its own history, especially given the improving profitability and growth trajectory. The PEG ratio is negative (-0.01) due to negative earnings growth in the past, but forward estimates indicate a return to profitability, making the PEG less meaningful.
PE
29.4x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 4x~139x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
20.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Ligand's inconsistent profitability is a key risk, with Q1 2026 net loss of -$13.3M despite high gross margins. The company's reliance on milestone payments creates revenue lumpiness, as seen in the swing from $115.5M in Q3 2025 to $51.7M in Q1 2026. While the balance sheet is strong (current ratio 22.2), the negative net margin of -25.8% in Q1 indicates that operating expenses and other charges can quickly erode earnings. The debt-to-equity of 0.44 is manageable, but any acquisition-related debt could increase financial leverage.
Market & Competitive Risks: The stock's trailing PE of 29.4x and PS of 13.6x are at a premium to the biotech sector, making it vulnerable to valuation compression if growth disappoints. With a beta of 0.98, the stock has market-like volatility, so a broad market downturn could impact its price. The XOMA acquisition integration poses execution risk, and any delays in realizing synergies could lead to analyst downgrades. Additionally, the short ratio of 4.25 days suggests some bearish positioning, which could amplify downside on negative news.
Worst-Case Scenario: If the XOMA acquisition fails to deliver expected synergies, revenue growth decelerates, and profitability remains elusive, the stock could fall to its 52-week low of $129.55, representing a -57.3% decline from the current price of $303.39. This scenario would likely involve multiple compression and analyst downgrades, with the low analyst target of $247 providing a more moderate downside of -18.6%.
FAQ
The primary risks are: 1) Inconsistent profitability – Q1 2026 net loss of -$13.3M shows earnings volatility. 2) High valuation multiples – trailing PE of 29.4x leaves little room for error. 3) Execution risk from the XOMA acquisition – integration challenges could delay expected synergies. 4) Revenue lumpiness – quarterly revenue can swing widely due to milestone payments. The most severe risk is a -57.3% decline to the 52-week low of $129.55 if growth disappoints.
The 12-month forecast is moderately bullish. The base case (50% probability) sees the stock trading between $247 and $326.63, with the average target of $311.30 as a midpoint. The bull case (30% probability) targets $326.63 to $388, driven by successful XOMA integration. The bear case (20% probability) sees a decline to $129.55-$247 if growth falters. The most likely scenario is the base case, assuming steady revenue growth and gradual margin improvement.
Ligand's trailing PE of 29.4x is above the biotech industry average, reflecting a premium for its royalty-based model and growth prospects. The forward PE of 26.3x suggests modest earnings growth is expected. Compared to its own history, the current PE is near the lower end of its historical range (which has exceeded 100x), so it is not excessively overvalued. The PS ratio of 13.6x is elevated, but the high gross margins justify some premium. Overall, the stock appears fairly valued given its growth trajectory and strong balance sheet, but it is not a bargain.
Ligand is a good buy for investors seeking a high-margin, asset-light biotech royalty aggregator with strong momentum and unanimous analyst support. The stock offers a 2.6% upside to the average target of $311.30 and a potential 27.9% upside to the high target of $388. However, the trailing PE of 29.4x and inconsistent profitability mean it is not without risk. It is best suited for growth-oriented investors with a long-term horizon who can tolerate quarterly earnings volatility. For value investors, the premium valuation may be a concern.
Ligand is more suitable for long-term investment due to its asset-light model, high margins, and potential for compounding royalty income. The stock's beta of 0.98 indicates market-like volatility, making it less ideal for short-term trading. The lack of dividends means returns come from price appreciation, which aligns with a long-term growth strategy. A minimum holding period of 3-5 years is recommended to allow the XOMA acquisition and pipeline to mature. Short-term traders may find opportunities around earnings events, but the stock's momentum could lead to sharp pullbacks.